Dr. Christopher Twelves on the Rising Issue of Metastatic Breast Cancer
Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed.
Christopher Twelves, MD, professor of Clinical Cancer Pharmacology and Oncology at the Leeds Institute of Cancer and Pathology, St James's Institute of Oncology, Leeds, UK, discusses the rising issue of metastatic breast cancer.
Twelves says a common misconception in breast cancer is that with the current flood of new treatments in HER2-positive breast cancer, the issue of breast cancer overall has been largely addressed. He adds that while this is not only untrue, the issue of metastatic breast cancer will become more and more of an issue as the years go on.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
November 22nd 2023In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.
Read More
